Standard of Care in CAR T-Cell Therapy

CAR T-cell therapy is a once-off, personalised treatment that uses a patient’s own reprogrammed T-cells to fight their cancer

This short video explains how CAR T-cell therapy harnesses a patient's own cells to fight cancer. 

You can also view the longer version of What is CAR T-cell therapy (animation by Maja Divjak)

Find out more information on how CAR T-cell therapy works 

Current CAR T-Cell therapy treatments (standard of care and clinical trials) 

Subsidised access to CAR T-cell therapy is available for eligible Australians:  

  • Adult patients with relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) 

  • Paediatric or young adult (up to 25 years) patients with relapsed or refractory Acute Lymphoblastic Leukaemia (ALL).  

The following CAR T-cell therapies are currently offered as standard of care:

Further CAR T-Cell therapy treatments

Further CAR T-cell therapies for the treatment of additional cancers are under review.

Patient prioritisation meeting 

The Centre of Excellence in Cellular Immunotherapy hosts a national, weekly CAR T patient prioritisation meeting where new patient referrals are discussed nationally to ensure fair and equitable access to standard of care CAR T-cell therapies, as well as available clinical trials.

CAR T-Cell therapy contact 

Health practitioners can find out more information about access to CAR T-cell therapy for patients by emailing This email address is being protected from spambots. You need JavaScript enabled to view it.

Pages related to CAR T-Cell Therapy